Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management

Bibliography

• Cushman M, Tsai AW, White RH, Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117(1):19-25
   PubMed Web of Science ®Google Scholar
• Cohen AT, Tapson VF, Bergmann JF, Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371(9610):387-94
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• Galanaud JP, Sevestre-Pietri MA, Bosson JL, Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 2009;102(3):493-500
   PubMed Web of Science ®Google Scholar
• Galanaud JP, Quenet S, Rivron-Guillot K, Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost 2009;7(12):2028-34
   PubMed Web of Science ®Google Scholar
• Vaitkus PT, Leizorovicz A, Cohen AT, Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005;93(1):76-9
   PubMed Web of Science ®Google Scholar
• Schwarz T, Buschmann L, Beyer J, Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 2010;52(5):1246-50
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Quintavalla R, Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood 2012;119(6):1561-5
   PubMed Web of Science ®Google Scholar
• https://ash.confex.com/ash/2012/webprogram/Paper46479.html
   Google Scholar
• Kahn SR, Shbaklo H, Shapiro S, Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord 2007;7:21
   PubMedGoogle Scholar
• Bauersachs R, Berkowitz SD, Brenner B, Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar A. Schellong Sea. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract 205]. American Society of Hematology 2011 Annual Meeting; 12 December 2011; San Diego, CA; 2011
   Google Scholar
• Schulman S, Eriksson H. Goldhaber Sea. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism [abstract O-TH-033]. ISTH 2011; 28 July 2011; Kyoto, Japan; 2011
   Google Scholar
• Schulman S, Baanstra D, Hea E. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism [abstract O-MO-037]. ISTH 2011; 25 July 2011; Kyoto, Japan; 2011
   Google Scholar
• The Equinox Investigators efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011;9(1):92-9
   Web of Science ®Google Scholar
• Enden T, Haig Y, Klow NE, Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012;379(9810):31-8
   PubMed Web of Science ®Google Scholar
• Rodger MA, Kahn SR, Wells PS, Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179(5):417-26
   PubMed Web of Science ®Google Scholar
• Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121(14):1630-6
   PubMed Web of Science ®Google Scholar
• Tosetto A, Iorio A, Marcucci M, Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012;10(6):1019-25
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Schenone A, Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366(21):1959-67
   PubMed Web of Science ®Google Scholar
• Brighton TA, Eikelboom JW, Mann K, Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. N Engl J Med 2012;
   PubMed Web of Science ®Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT01578122?term=01578122&rank=1
   Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT01429714?term=elastic+compression+stocking&rank=3
   Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT00643201?term=00643201&rank=1
   Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT00986154?term=00986154&rank=1
   Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT00421538?term=NCT00421538&rank=1
   Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT01467583?term=NCT01467583&rank=1
   Google Scholar
• Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspect Vasc Surg Endovasc Ther 2009;21(4):221-4; quiz 24-5
   PubMedGoogle Scholar
• Leizorovicz A, Siguret V, Mottier D, Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep(R) in Renal Insufficiency Study (IRIS). Thromb Res 2011;128(1):27-34
   PubMed Web of Science ®Google Scholar
• Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost 2011;9(10):1966-72
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123(21):2363-72
   PubMed Web of Science ®Google Scholar
• Palareti G, Leali N, Coccheri S, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348(9025):423-8
   PubMed Web of Science ®Google Scholar
• Palareti G, Hirsh J, Legnani C, Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 2000;160(4):470-8
   PubMedGoogle Scholar
• Davidson BL, Buller HR, Decousus H, Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007;5(6):1191-4
   PubMed Web of Science ®Google Scholar
• Al-Yaseen E, Wells PS, Anderson J, The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005;3(1):100-2
   PubMed Web of Science ®Google Scholar
• Barba R, Marco J, Martin-Alvarez H, The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005;3(5):856-62
   PubMed Web of Science ®Google Scholar
• Wallace JL, Reaves AB, Tolley EA, Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis 2012;
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol 2012;68(5):757-65
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70(5):703-12
   PubMed Web of Science ®Google Scholar
• Mueck W, Lensing AW, Agnelli G, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50(10):675-86
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Eriksson H, Wahlander K, Gustafsson D, A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1(1):41-7
   PubMed Web of Science ®Google Scholar
• Schulman S, Lundstrom T, Walander K, Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study. Thromb Haemost 2005;94(4):820-4
   PubMed Web of Science ®Google Scholar
• Fiessinger JN, Huisman MV, Davidson BL, Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293(6):681-9
   PubMed Web of Science ®Google Scholar
• Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6(8):1313-18
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7
   PubMed Web of Science ®Google Scholar
• http://www.clinicaltrials.gov/ct2/show/NCT00633893?term=00633893&rank=1
   Google Scholar
• Buller HR, Davidson BL, Decousus H, Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140(11):867-73
   PubMed Web of Science ®Google Scholar
• Buller HR, Cohen AT, Davidson B, Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007;357(11):1094-104
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007;120(1):72-82
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12(4):389-96
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Gebska M, Kadziola Z, Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003;89(4):674-80
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162(15):1729-35
   PubMed Web of Science ®Google Scholar
• Ramacciotti E, Araujo GR, Lastoria S, An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 2004;114(3):149-53
   PubMed Web of Science ®Google Scholar
• Chong BH, Brighton TA, Baker RI, Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005;19(3):173-81
   PubMed Web of Science ®Google Scholar
• Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005;29(6):638-50
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 2008;48(4):953-9
   PubMed Web of Science ®Google Scholar
• Romera A, Cairols MA, Vila-Coll R, A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009;37(3):349-56
   PubMed Web of Science ®Google Scholar
• Agnelli G, Prandoni P, Becattini C, Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139(1):19-25
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Anderson DR, Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004;2(5):743-9
   PubMed Web of Science ®Google Scholar
• Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002;24(3):209-14
   PubMed Web of Science ®Google Scholar
• Partsch H, Kaulich M, Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol 2004;23(3):206-12
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Prins MH, Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004;141(4):249-56
   PubMed Web of Science ®Google Scholar
• Aschwanden M, Jeanneret C, Koller MT, Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg 2008;47(5):1015-21
   PubMed Web of Science ®Google Scholar
• Turpie A, Bauer K, Caprini J, Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of VTE after major abdominal surgery. 2005. Results of the APOLLO study [abstract]. XX Congress ISTH 2005; 2005
   Google Scholar